No retraction, correction or concern found when last checked on Oct 20, 2026.
Targeting Cell Death: Pyroptosis, Ferroptosis, Apoptosis and Necroptosis in Osteoarthritis
Jian Yang, Shasha Hu, Yangyang Bian and 6 more
Frontiers in Cell and Developmental Biology · 2022 · Review · CC BY
Abstract
New research has shown that the development of osteoarthritis (OA) is regulated by different mechanisms of cell death and types of cytokines. Therefore, elucidating the mechanism of action among various cytokines, cell death processes and OA is important towards better understanding the pathogenesis and progression of the disease. This paper reviews the pathogenesis of OA in relation to different types of cytokine-triggered cell death. We describe the cell morphological features and molecular mechanisms of pyroptosis, apoptosis, necroptosis, and ferroptosis, and summarize the current research findings defining the molecular mechanisms of action between different cell death types and OA.
Full text
From PubMed Central, U.S. National Library of Medicine, as current on Oct 20, 2026. Paragraph numbers are ours, so an answer can point at one.
Introduction
Cell death plays a key role in the development of the body and maintains homeostasis to prevent the development of diseases. Classically, apoptosis and necrosis were viewed as the main types of cell death, however, this paradigm continues to evolve. Cell death can be defined as programmed and non-programmed forms based on the regulation of the processes involved.
Programmed cell death (PCD) can be divided into lytic and non-lytic cell death. Non-lytic cell death mainly refers to apoptosis which can produce apoptotic bodies that are cleared by phagocytes and does not involve the inflammatory response. Lytic forms of cell death include necroptosis and pyroptosis. These forms of cell death lead to leakage of intracellular components including damage-associated molecular pattern molecules (DAMPs) which in turn activate a strong inflammatory response also known as inflammatory death.
Non-programmed cell death (Non-PCD) generally refers to necrosis which describes the process of irreversible cell damage and final cell death caused by physical or chemical stimulation in extreme environments. The main characteristics of necrosis include the destruction of cell membranes, edema of cells and organelles (cytoplasmic vesicles), and the release of cell contents, however, chromatin does not agglutinate during necrosis.
A new type of cell death termed ferroptosis, was proposed by Stockwell in 2012. Ferroptosis is a form of programmed cell death driven by iron-dependent lipid peroxidation. The ferroptosis is characterized by changes in the mitochondrial phenotype, mitochondrial atrophy, and an increase of membrane density. Different types of cell death have been shown to regulate the development of multiple chronic diseases.
Osteoarthritis (OA) is a chronic degenerative disease with progressive features. OA involves structures all parts of the joints in which undergo structural damage and functional imbalances occur as a result of multiple factors. The influence of different types of cell death on the development of OA has become a new research hotspot. The purpose of this review is to summarize the pathogenesis of OA and to explore research opportunities focusing on mechanisms of cell death including pyroptosis, apoptosis and ferroptosis.
Osteoarthritis
OA is a common and complex chronic disease that affects 250 million people worldwide. Due to an aging population and a rise in obesity, OA has become the fourth largest disabling disease in the world. It is estimated that the medical cost of OA accounts for 1–2.5% of GDP in different high-income countries. OA is associated with all parts of the joints and involves structural changes in hyaline articular cartilage, subchondral bone, ligaments, joint capsule, synovium and muscles around the joint. OA involves metabolic, inflammatory, mechanical and other factors leading to structural damage and repair imbalances. Currently, the main risk factors associated with OA are age, female sex, obesity, hip deformities, weight-bearing work, exercise, diabetes, hypertension, cardiovascular disease, depression and hereditary factors.
Chondrogenic progenitor cells (CPCs) are mesenchymal stem cells that differentiate into chondrocytes and are also known as cartilage precursor cells. Chondrocytes and the extracellular matrix are the main components of articular cartilage. No blood vessels or nerves are present in the cartilage matrix, and chondrocytes are the only cellular components present in the articular cartilage matrix. Under physiological conditions, chondrocytes maintain the lowest level of collagen turnover and do not show mitotic activity. Collagen turnover gradually increases with risk factors such as age, mechanical stress, diabetes and hypertension. Subsequently, the composition and structure of the cartilage matrix change resulting in the formation of fibrous tissue. As this pathological process progresses, deep fissures develop that are related to the shedding of cartilage fragments and eventually lead to the delamination and exposure of calcified cartilage and bone. In the early stages of this process, the surface receptors of chondrocytes inhibit the low collagen turnover rate of chondrocytes through integrins and other related factors. The synthetic activity of chondrocytes also increases significantly due to the repair of the perichondrial matrix which finally develops to invade the collagen network. This marks the irreversible progression of OA. Also, increases in chondrocyte activity result in the increased production of inflammatory reactive proteins including interleukin-1β (IL-1β), interleukin-6, tumor necrosis factor-α (TNF-α) and matrix metalloproteinases (MMP1, 3 and 13).
Injury to the bone and cartilage around the joint is an important factor in OA. The subchondral bone tissue is composed of cortical and cancellous bone. As AO progresses, the volume, thickness and outline of the cortical bone gradually increase. Also, the trabecular structure and bone mass of the subchondral bone change as bone cysts form along with the appearance of osteophytes. A characteristic feature of the OA is the gradual thickening of the subchondral plate that reflects changes in mechanical loading owing to cartilage damage and properties of the subchondral bone. Shanchez et al., reported that osteoblasts can express inflammatory cytokines and degrading enzymes in response to mechanical stimulation and chondrocytes that can in turn act on cartilage or subchondral bone to increase the severity of OA.
Synovitis is a common feature of OA. The synovium includes the synovial membrane and the fluid. The synovium is a thin cell layer arranged in the joint cavity that contains macrophages and fibroblasts that regulate the trafficking of molecules through the joint. The release of inflammatory factors and the secretion of degrading enzymes in the synovial tissue are correlated with the severity of OA. Proteases released by chondrocytes increase the production of pro-inflammatory cartilage degradation products that interact with DAMPs, Toll-like receptors (TLRs) and integrin. These changes further aggravate inflammation and catabolic products to increase the severity of OA. Baker and Roemer et al. reported that the risk of synovitis progression and OA was positively correlated with joint symptoms through MRI analysis. IL-1, IL-6, IL-15, tumor necrosis factor (TNF), prostaglandin E2, matrix metalloproteinases (MMP1, 3 and 13) and collagenase (coLI, II) have also been detected in the synovial fluid, cartilage and the synovium of patients with OA.
Pyroptosis
The first experimental observations of lytic death were made over 30 years ago when it was reported that Shigella fowleri could induce lytic death in infected host macrophages. This form of lytic death has characteristics that are common to apoptosis such as chromatin agglutination, DNA fragmentation and cysteinyl aspartate specific proteinase (Caspase) activity dependence. This mode of death was initially considered to be apoptosis, yet, it was not until 2001 that Cookson et al. showed that this form of cell death depends on Caspase-1 activity which is different from Caspase-3 activity-dependent apoptosis. For the first time, the authors defined pyroptosis as a form of Caspase-1-dependent cell death. The term originates from “pyro” meaning fire, indicating that this kind of programmed cell death causes inflammation, and “ptosis” means falling, indicating the nature of programmed cell death. When cells undergo pyroptosis, the nucleus becomes concentrated and the chromatin DNA is randomly broken and degraded. Pores in the cell membrane regulate the trafficking of substances to and from cells. As this process becomes imbalanced, osmotic swelling occurs and the membrane breaks releasing the cell contents that contain molecules to stimulate the immune response. During the process of cell death, the nucleus becomes condensed and rounded yet the nuclear integrity remains unchanged.
Pyroptosis mainly leads to the splicing and polymerization of members of the Gasdermin family (such as GSDMD). It can also activate cell perforation and death through inflammatory corpuscle activation and caspases. Based on the different mechanisms of caspase-mediated cell death, pyroptosis can be defined as caspase-1 and caspase-4/5/11 types (Figure 1). Pyroptosis induced by caspase-1 activation mainly occurs in macrophages and dendritic cells. Caspase-4/5/11 activation can also cause pyroptosis in macrophages and other non-macrophage cell types (Kayagaki, Warming et al., 2011).
Gasdermin proteins are a family that has multiple functions and are expressed in a variety of cell types and tissues. Human gasdermin proteins are composed of Gasdermin A (GSDMA), Gasdermin B (GSDMB), Gasdermin C (GSDMC), Gasdermin D (GSDMD), Gasdermin E (GSDME, also known as DFNA5) and Pejvakin (PJVK, also known as DFNB59). Except for PJVK, all gasdermin proteins have conserved double domain arrangements including a C-terminal (GSDM-C) and N-terminal domains (GSDM-N). The N terminal has a pore-forming activity and can induce pyroptosis. GSDMD can be specifically activated by caspases-1, 4, 5, 11, and can be cut by caspase-1 and 11 into GSDMD-N (p30 fragment) and GSDMD-C (p20 fragment). The activated GSDMD-N domain has lipophilic characteristics and can be transported from the cytoplasm to the cell membrane. The N-terminus of gasdermin can directly interact with membrane lipids and oligomerize to form 10–33 nm pores. New research has shown that intracellular IL-1β can be released outside the cell through channels formed by GSDMD. When exposed to inflammation or hyperactivating stimuli, GSDMD and caspase-11 can form larger pores in the liposomes of cell membranes leading to a massive release of IL-1β which in turn causes pyroptosis. Recently, it has been demonstrated that when GSDME is stimulated by chemotherapeutic agents, tumor necrosis factor (TNF) and viral infection, it is activated by caspase-3 which is involved in apoptotic signaling. GSDME then releases the activated N-terminal end causing perforation of the cell membrane which converts cells that should undergo apoptosis into pyroptosis. These data further suggest that the regulation of cell death is highly complex and dependent on the mode of death.
The main types of inflammasomes include NLRP3, NLRP1, NLRC4 and AIM2. The basic structure of inflammasomes consists of pattern recognition receptors (PRRs), apoptosis-associated speck-like protein containing a CARD (ASC) and pro-caspase-1 (CASP1) (Man and Kanneganti, 2015; ). Inflammasomes are multimeric protein complexes that assemble in the cytosol and act as platforms for caspase activation. When cells sense inflammation or the invasion of viral microbes, they respond by damaging tissues. A series of cascade reactions mediated by the TLRs are initiated to activate nuclear factor-κB (NF-κB), mitogen-activated protein kinase (MAPK) and interferon signaling pathways leading to cell activation and the production of related inflammatory cytokines. These include tumor necrosis factor (TNF), interleukin-6 (IL-6), interleukin-8 (IL-8) and type I interferons (IFNs) in response to extracellular inflammatory stimulation signals. Nod-like receptors (NLRs) also play an important role in the perception of inflammation or viral invasion. Oligonucleotide binding of NLRs to domain-containing protein 1 (NOD1) and NOD2 triggers a signaling cascade after ligand recognition that is similar to the cascade initiated by TLRs and which leads to the production of inflammatory cytokines. The other part of the NLR mediates the activation of caspase 1 which triggers caspase 1-dependent pyroptosis and releases inflammatory cytokines IL-18 and IL-1β. TLR, NOD1 and NOD2 coactivate caspase1 and produce large amounts of IL-1β.
Research Related to Osteoarthritis and Pyroptosis
Currently, only a few studies have investigated the mechanism of interaction between OA and pyroptosis and most studies have focused on the role of the NLRP3 inflammasome (Table 1). NLRP3 inflammasomes have an important role in the pathogenesis of autoinflammation, cancer and degenerative diseases. In OA, perichondral synovial cells stimulated by DAMPs lead to the increased release of the NLRP3 inflammasomes, IL-1β and IL-18 on the cartilage surface to further exacerbate inflammatory cytokine production and promote pyroptosis. Shuya Wang et al. reported that activation of the AMPK signaling pathway by exogenous stromal cell-derived factor-1 (SDF-1) inhibits the NLRP3 inflammasome which in turn inhibits the scorching process of osteoarthritic synovial cells. P2X7R is a purinoceptor that is a non-selective cation channel gated by adenosine triphosphate. P2X7R mediates Na and Ca influx and K efflux, and is involved in a variety of inflammatory responses and different mechanisms of cell death. P2X7R participates in NLRP3 and caspase-11 distinct pathway-mediated pyroptosis and produces cartilage degrading enzymes to activate inflammatory factors in synovial tissue. Activated P2X7 promotes extracellular matrix degradation and pyroptotic inflammation in OA chondrocytes through NF-κB/NLRP3 crosstalk to aggravate the symptoms of OA.
Recent studies have shown that the combined effect of disulfiram and glycyrrhizic acid at standard concentrations protects chondrocytes, inhibits the inflammatory responses and reduces pyroptosis. Ubiquitin (Ub)-specific proteases (USPs), also known as deubiquitinating enzymes, remove Ub from Ub conjugates and regulate a variety of cellular processes. USP7 is a member of the ubiquitin-specific proteases. USP7 inhibitors attenuate H2O2-induced chondrocyte damage and pyroptosis by inhibiting the NOX4/NLRP3 signaling pathway.
The therapeutic role of Chinese medicine in the management of OA is gaining increasing attention. For example, Morroniside significantly inhibits the NF-κB signaling pathway, decreases the expression of NLRP3 and Caspase-1, and reduces the nuclear translocation of p65, thereby inhibiting the onset of pyroptosis and delaying the progression of OA. Chondrocyte pyroptosis is inhibited by licochalcone A (Lico A) through inhibition of the NLRP3 inflammasome. Jiaming Hu et al. reported that loganin ameliorates cartilage degeneration and the development of OA in a mouse model through inhibition of NF-κB activity and pyroptosis in chondrocytes. In animal models, Icariin (ICA) attenuates chondrocyte damage and OA by inhibiting the NLRP3 signaling-mediated caspase-1 pathway to reduce pyroptosis (Zu et al., 2019). NLRP1 and NLRP3 inflammasomes mediate the onset of pyroptosis in knee OA (KOA) via the Caspase-l/IL-1β inflammatory pathway. Shi et al. showed that increased lipopolysaccharide (LPS) and ATP in joint-space may promote KOA by NLRP3 Inflammasome. Overall, the role of inflammasomes such as NLRP3 and its regulators in pyroptosis suggests that NLRP3 may be a promising biomarker for the diagnosis and monitoring of OA. Therapeutic targeting of NLRP3 may be a potential strategy for the treatment of OA.
Ferroptosis
Ferroptosis is a newly discovered form of regulated cell death that differs from the traditional cell death programs of necrosis, apoptosis, and pyroptosis that are caused by iron-dependent and lethal lipid peroxidation. Ferroptosis was first proposed by Dixon in 2012 and describes a form of cell death induced by the small molecule Erastin which inhibits cystine import leading to glutathione depletion and inactivation of the phospholipid peroxidase glutathione peroxidase 4 (Gpx4). GPX4 converts potentially toxic lipid hydroperoxides (L-OOH) to non-toxic lipid alcohols (L-OH). Inactivation of Gpx4 by depletion of GSH with Erastin or with a direct Gpx4 inhibitor, (1S,3R)-RSL3, ultimately leads to overwhelming lipid peroxidation and cell death.
Inactivation of GPX4-RSL3 directly induces ferroptosis. Erastin and RSL3 were first identified as ferroptosis-inducing compounds. Erastin inhibits the transfer of cysteine causing loss. Cysteine is an essential component of glutathione and so indirectly induces ferroptosis. Ferroptosis can be suppressed by iron chelators, lipophilic antioxidants, inhibitors of lipid peroxidation, and depletion of polyunsaturated fatty acids. This process also correlates with the accumulation of markers of lipid peroxidation. Recent studies suggest that mobilization and upregulation of the transferrin receptor (TfR) can be a potential marker of iron death. In contrast to other forms of programmed cell death, ferroptosis exhibits specific morphological and biological features (Table2).
The Relationship Between Ferroptosis and Disease
The mechanisms of interaction between ferroptosis-inducing compounds and ferroptosis signaling pathways remain to be fully elucidated. A growing body of experimental evidence suggests that excessive iron contributes to oxidative tissue damage and organ dysfunction resulting in the development of cirrhosis, cardiomyopathy, diabetes and other diseases. In an animal model of traumatic brain injury (TBI), ferroptosis was shown to be involved in acute central nervous system (CNS) trauma based on glutathione peroxidase activity, lipid-responsive oxygen species and observations of mitochondrial shrinking. The characteristic products of ferroptosis have also been demonstrated in spinal cord injury and the source of iron is closely related to red blood cell rupture, hemolysis.
The role of ferroptosis in the treatment of hepatocellular carcinoma has also been a research focus. Urano et al. showed that the combination of iron inhibitors and anti-angiogenic drugs enhanced the tumor-killing effects of sorafenib by inducing cell cycle arrest and apoptosis. Studies from as early as 1992 have observed selective accumulation of iron in Aβ aggregation areas and neurofibrillary tangles in the brain in Alzheimer’s disease. Ayton et al. showed that excessive accumulation of iron in the brains of Alzheimer’s patients may be associated with accelerated cognitive decompensation.
Currently, very few studies have focused on the role of ferroptosis in OA. Recent research findings from the past 2 years are summarized in Figure 2. Yao X et al. used chondrocytes extracted from the knee joints of C57BL/6J mice as an in vitro experimental model of OA using interleukin-1β and ferric ammonium citrate to mimic the inflammatory response and iron overload. The study demonstrated that ferrostatin-1 attenuates IL-1β and Fac induced cytotoxicity, the accumulation of reactive oxygen species (ROS) and lipid-ROS, and the expression of ferroptosis-related proteins to promote activation of the NRF2 antioxidant system. This was the first study to demonstrate that chondrocytes underwent ferroptosis in vitro.
In a lipopolysaccharide (LPS)-induced OA cell model, icariin (ICA) reduced the expression of iron transport factor TFR1. ICA activated the Xc-/Gpx4 axis to exert an inhibitory effect on the expression of Gpx4, SLC7A11 and SLC3A2L which acted to significantly reduce cell death in induced cells and inhibit ferroptosis. Zhang et al. identified a new subpopulation of chondrocytes located in the nucleus pulposus of the intervertebral disc using single-cell RNA-seq analysis. The study revealed the presence of ferroptosis during disc degeneration.
Ferroptosis has also been shown to have an important role in the development of cancer and inflammatory and chronic diseases. In OA, high concentrations of iron can promote joint degeneration and facilitate the development of OA. However, evidence from relevant studies is lacking and the detailed molecular mechanisms by which iron compromises to cartilage remains to be understood.
Apoptosis
Apoptosis is the active, physiological process of cell death that is activated under specific physiological or pathological conditions. Apoptosis is regulated by intrinsic genetic mechanisms of autologous damage to the organism. Apoptosis is regulated by apoptosis-related genes and so the process is also known as programmed cell death (PCD) or type I cell death.
The concept of apoptosis was first introduced by Kerr, Wyllie and Currie in 1972. “Apoptosis” is a Greek word meaning “to leave or fall” implying that apoptosis occurs when a cell dies similar to the natural withering of leaves or flowers. This metaphor emphasizes that apoptosis is an important part of the normal life cycle of an organism, and that it is an active process under strict genetic control. Apoptosis has a wide range of biological functions during the development and differentiation of the organisms, in immune regulation, and the maintenance of tissue stability. The process is also involved in the removal of redundant or harmful cells and the prevention of cancer.
Apoptosis is morphologically characterized by reductions in cell size, loss of connections, and detachment from surrounding cells. The cytoplasmic density gradually increases and the mitochondrial membrane potential disappears. During apoptosis, the nucleoplasm becomes concentrated in the nucleus, the nucleolus becomes broken, and DNA is degraded into 180–200 bp fragments. The entire cell has an intact cytosolic structure with vesicle formation which eventually divides and wraps the apoptotic cell into several apoptotic vesicles. This process does not involve the release of cellular contents and the inflammatory response is not activated.
Apoptosis can be defined as either extrinsic or intrinsic depending on the stimulus (Figure 3). Extrinsic apoptosis is also known as the death receptor apoptotic pathway and intrinsic apoptosis refers to the mitochondrial apoptotic pathway. Death receptors refer to Fas (also known as DR2, APO-1, or CD95), tumor necrosis factor receptor 1 (TNFR1) or tumor necrosis factor-associated apoptosis-inducing ligand receptor (TRAILR), all of which are members of the Tumor Necrosis Factor Receptor Superfamily (TNFRSF).
Death receptors are transmembrane glycoproteins located on the surface of cell membranes that cause conformational changes in cell membrane delivery when receiving death ligands from extrinsic apoptotic signaling pathways and rapidly activate caspase ultimately leading to apoptosis. The engagement of the death receptor, Fas, binds to its ligand FasL to assembly a typical multiprotein complex called the death-inducing signaling complex (DISC). DISC formation allows the recruitment and activation of initiator caspase-8, mediated by the Fas-associated protein with death domain (FADD) adaptor molecule. The recruitment of caspase-8 leads to autoproteolytic cleavage and subsequent activation. The active fragment of caspase-8 propagates apoptotic signals by activating caspase-3 fragment activity which further catabolizes cellular components.
Fas is involved in regulating the DISC-mediated production of active caspase-8 and activates caspase-9 prior to activation of caspase-3. Intrinsic apoptosis triggers include intracellular damage, cytokine withdrawal, DNA damage, oxidative or endoplasmic reticulum (ER) stress, and cytosolic Ca2+ overload. These stimuli ultimately activate members of the BCL2 family of proteins located primarily in the mitochondria and endoplasmic reticulum and have contrasting effects on cell fate. For example, Bcl-xs, Bcl-GL, Bok, Bax, and Bak can promote apoptosis, whilst A1, Mcl-1, Bcl-B, Bcl-2, Bcl-x, and Bcl-w can prevent apoptosis.
The proteins that lead to apoptosis can be functionally classified based on whether they can function independently of caspases (i.e., Omi/HtrA2, apoptosis-inducing factor AIF) or activate caspases either directly or indirectly (e.g., Smac/DIABLO, cytochrome c). Apoptosis protease-activating factor-1 (APAF-1) is a key component of the apoptosome. Cytochrome c can activate APAF-1 whilst forming an activation platform for the caspase-9 promoter in the mitochondrial pathway by oligomerization with APAF-1. Activated caspase-9 further activates caspases-3 and -7, which in turn activate caspases-2,-6,-8,-10 forming a positive feedback loop that amplifies apoptosis signals and induces apoptosis.
Signaling Pathways Involved in Osteoarthritis and Apoptosis
Recent studies focused on apoptosis of articular chondrocytes in OA involve the inflammatory response, signaling pathways and target modulation. Interleukin-1β (IL-1β) is an important inflammatory factor that belongs to the interleukin-1 (IL-1) family and plays a key role in the pathogenesis of OA. IL-1β increases apoptosis in articular chondrocytes by stimulating the expression of TNF, Fas-associated death region protein, and Caspases-3, and -8.
Current research has focused on the role of non-coding RNAs regulating IL-1β-mediated apoptosis in chondrocytes. Recent studies demonstrate that the LINC00623/miR-101/HRAS axis modulates chondrocyte apoptosis, senescence and extracellular matrix (ECM) degradation in OA through MAPK signaling. Also, it has been shown that miR-27a is a regulator of the PI3K-Akt-mTOR axis in human chondrocytes that could be involved in OA. Junkui Xu et al. reported that LncRNA SNHG7 alleviates IL-1β-induced OA by inhibiting miR-214-5p-mediated PPARGC1B signaling pathways.
The tumor necrosis factor (TNF) superfamily is a group of cytokines produced by a variety of cell types including macrophages. TNF plays a key role in immunity, inflammation, and the control of cell differentiation, proliferation, and apoptosis. TNF-α is one of the most important signaling molecules in this family. TNF-R1 mediates most of the biological functions of TNF-α and contains a death structural domain. TNF-R1 can induce apoptosis by activating the NF-κB, JNK and MAPKs signaling pathways.
The combination of long-stranded non-coding RNA (LncRNA) and microRNA (MiRNA) has gradually replaced single, localized research approaches as the main approach to study the roles of these molecules in OA today. Xu Kai et al. reported that LncRNA PVT1 induces chondrocyte apoptosis through upregulation of TNF-α in synoviocytes by sponging miR-211-3p. Wang Yingjie et al. reported that MiR-140-5p inhibits the PI3K/AKT signaling pathway and suppresses the progression of OA by targeting HMGB1.
Mitogen-activated protein kinases (MAPKs) are a class of serine/threonine protein kinases that are widely present in eukaryotic cells. MAPKs are activated by extracellular signals, physical stimuli, and inflammatory cytokines. They also regulate the activity of transcription factors to control the expression of related genes and elicit cellular responses. The MAPK subfamily includes p38mapk, extracellular regulated protein kinases (ERK) and c-Jun N-terminal kinase (JNK). JNK can promote the expression of apoptotic genes by phosphorylating c-jun and by increasing the expression of proteins related to the Fas/FasL signaling pathway. Conversely, JNK induces phosphorylation and inactivation of related anti-apoptotic proteins to promote apoptosis in OA. Fas signaling can initiate apoptosis by activating caspase-8 which in turn can activate the downstream effector caspase-3.
Notch signaling is an evolutionarily conserved pathway that plays an important regulatory role in cell fate determination, proliferation, differentiation, and dynamic homeostasis. The Notch signaling pathway also plays an important role in proliferation and differentiation during chondrogenesis and in the development of cartilage. The Notch pathway consists primarily of Notch receptors, Notch ligands, and downstream target genes. In post-traumatic OA, the Notch pathway is highly activated in human and mouse joint tissues. Notch1, JAG1 and other downstream target genes are overexpressed in OA tissue biopsies. However, in a mouse model, loss of Notch signaling in OA indicated an important role in maintaining osteoarticular cartilage growth. Also, intra-articular injection of the Notch complex inhibits cartilage degeneration in a mouse OA model. Overall, a dual role for Notch signaling in maintaining the normal physiological function of articular cartilage and promoting the progression of OA has been observed. In short, Notch signaling plays a complex role in cartilage homeostasis and transient or physiological Notch signaling in chondrocytes favors a balanced anabolic and catabolic response. In contrast, sustained or enhanced Notch activity elicits a pathological response through the simultaneous suppression of chondrogenic genes and the induction of genes encoding catabolic factors.
Melatonin (N-acetyl-5-methoxytryptamine) is a molecule that is produced primarily by the pineal gland and other organs that acts to reduce peroxidative damage in the body. Melatonin plays an important role in inflammation, apoptosis, proliferation, and metastasis. It has also been shown to have a protective role in chronic diseases including OA, osteoporosis, COVID-19, Parkinson’s, Alzheimer’s, cancer, and sepsis.
Melatonin prevents apoptosis and promotes cell survival by inhibiting p38, phosphorylation of JNK MAPKs, and p53 activation by limiting cytochrome c release and activating procaspases proteases. LIM et al. investigated the effects of melatonin on human chondrocytes and rabbit OA models. The study showed that melatonin inhibits H2O2-induced cytotoxicity, suppresses the production of NO and PEG2 production, and blocks the H2O2-induced release of TNF- α, IL- 1β, and IL- 8. Animal experiments have shown that intra-articular injection of melatonin protects articular cartilage by targeting miR-140. This acts to prevent the disruption of cartilage matrix homeostasis and slows the progression of surgically induced OA in mice.
Currently, apoptosis is an important focus of OA research as an increasing number of signaling pathways have been shown to be involved. The interaction between non-coding RNA and OA is subject to ongoing investigations. Further elucidation of the respective roles of apoptosis and non-coding RNAs may facilitate the development of novel gene therapy and targeted approaches for the treatment of OA.
Necroptosis
It was more than 2 centuries ago that pathologists determined that necrosis was a cause and consequence of disease. 100 years later, apoptosis was first discovered. Previous studies identified the pathophysiological importance of necroptosis in myocardial infarction and stroke, atherosclerosis, ischemia-reperfusion injury, pancreatitis, inflammatory bowel disease, and several other common clinical disorders.
Necrosis has long been described as the exposure of cells to extreme physicochemical stresses resulting in rapid cell death. However, necrosis can be induced under different stimulatory conditions (e.g., inflammatory factors, interferon-g (IFN-g), ATP depletion, ischemia-reperfusion injury, and pathogens) with steps and signaling events similar to the cell death program. This process of regulated necrosis is referred to as necroptosis. Morphological changes during necroptosis include a translucent cytoplasm, swelling of the organelles, permeabilization of the lysosomal and plasma membranes, increased cell volume (oncosis), and mild chromatin condensation (Table 2).
In contrast to apoptosis and pyroptosis, necroptosis is a caspase-independent death program. Necroptosis is programmed necrotic cell death caused by RIP1/RIP3 and MLKL under various pathological conditions. Apoptosis and necroptosis are closely related, and TNF can determine the final fate of cells. Once TNF binds to TNF receptor 1, TNF induces receptor trimerization and recruits the death domain (DD)-containing adaptor proteins TRADD, TRAF2, and RIP1 to form the so-called complex I. Several components of complex I recombine to form a cytosolic complex (complex II) that recruits FADD (Fas-associated via DD) via DD-mediated interactions. In complex II, FADD recruits procaspase-8, whilst RIP1 recruits RIP3. When RIP3 is absent or present at low levels, caspase-8 can activate automatically and the cell undergoes apoptosis.
In contrast, in the presence of high concentrations of RIP3, complex II tends to recruit large amounts of this protein and turns itself into a so-called necrosome. Procaspase-8 in the necrosome cleaves RIP1 and RIP3 preventing the initiation of the necroptosis. Therefore, the development of necroptosis requires inhibition of caspase-8 activity. RIP3 can be auto-phosphorylated in response to homo-interactions. Auto-phosphorylated RIP3 recruits and phosphorylates the mixed-lineage kinase domain-like protein (MLKL). Phosphorylated RIP3 recruits and phosphorylates MLKL leading to MLKL oligomerization and translocation to the plasma membrane. MLKL oligomers execute necroptosis by generating cation channels causing plasma membrane rupture. Recent studies have identified MLKL as the most important working protein for plasma membrane rupture.
In summary, RIP1 deubiquitination is critical for necrosome assembly and activation, whilst RIP3 determines the susceptibility of cells to move towards necroptosis which is ultimately executed by phosphorylated MLKL.
Necroptosis and Orthopaedic-Related Diseases
Emerging studies have focused on the link between necrosis and orthopaedic-related diseases. Osteoporosis is a systemic bone disease characterized by low bone mass and degenerative damage to the ultrastructure of bone trabeculae resulting in increased bone fragility and susceptibility to fractures. In 2016, Cui et al. constructed an ovariectomy-induced osteoporosis rat model and found that the levels of RIP1, RIP3, and MLKL proteins were significantly elevated in rat femurs and a large number of necrotic osteocytes with positive TUNEL staining but negative caspase-3 staining were seen. The study also showed that administration of necrostatin-1 (Nec-1) significantly reduced the expression of RIP1, RIP3 levels and inhibited programmed necrosis of osteoblasts to reverse bone loss. Studies have found that excessive alcohol consumption leads to activation of RIPK1/RIPK3/MLKL signaling which increases necrotrophic apoptosis of osteoblasts and reduces osteogenic differentiation and bone formation in vivo and in vitro, leading to the development of osteoporosis.
Lumbar disc herniation (LDH) is a syndrome in which the lumbar disc degenerates and the nucleus pulposus protrudes outwards either alone or together with the fibrous ring and cartilage endplates. This causes irritation or compression of the sinus nerve and nerve roots with lumbar and leg pain as the main symptom. The pathogenesis of lumbar disc herniation includes disc degeneration, mechanical stress injury, immune inflammation, and imbalance of extracellular matrix metabolism. Necroptosis and lumbar disc herniation are closely associated processes. Recent studies have shown that necrosulfonamide (NSA) protects intervertebral disc degeneration via necroptosis and apoptosis inhibition. Chen et al. demonstrated in an in vivo model that RIPK1-mediated mitochondrial dysfunction and oxidative stress play a crucial role in NP cell necroptosis and apoptosis during compression injury. The synergistic regulation of necroptosis and apoptosis may exert more beneficial effects on NP cell survival to ultimately delay or prevent intervertebral disc degeneration.
Research on the role and mechanisms of necroptosis in OA is becoming an area of increasing interest. Recent evidence suggests that oxidative and mechanical stresses can contribute to the development of necroptosis in OA (Figure 4). Mechanical stress also mediates apoptosis and necroptosis in mandibular cartilage via RIP1. Cheng et al. demonstrate that upregulation of RIP1 contributions to OA pathogenesis by mediating chondrocyte necroptosis and ECM destruction via BMP7, a newly identified downstream target of RIP1, in addition to MLKL. Chen et al. reported that PLCγ1 inhibition combined with inhibition of apoptosis and necroptosis increases cartilage matrix synthesis in IL-1β treated rat chondrocytes. Also, recent evidence has shown that perturbation of the TRIM24-RIP3 axis regulates mouse osteoarticular pathogenesis by activating RIP3 kinase and regulating the expression of catabolic factors.
In summary, the development and progression of OA is closely related to RIP1 and RIP3. Recent studies have suggested that necroptosis has an important position in inflammation-related diseases. Necroptosis and apoptosis are closely related highlighting the complexity and diversity of mechanisms of disease.
Discussion and Perspectives
OA is a complex chronic disease that is affected by age, gender, weight, mechanical injury and joint deformity. The number of people affected and the cost of medical treatment are increasing every year, hence there is a need for improved OA treatment options. The current pharmacological approach to treating OA is mostly palliative and surgery remains the ultimate option for patients. As the understanding of the etiology and pathogenesis of OA improves, more and more potential targets are being used to prevent the development and progression of the disease. The relationship between the pathogenesis of OA and different cell death types is likely to remain a future research focus.
During the development of OA, inflammatory mediators such as ROS, interleukins, NO, and MMP are closely related to chondrocyte apoptosis that involves the mitochondrial, death receptor and JNK signaling pathways. These signaling pathways are directly related to apoptosis in chondrocytes and regulate gene targets, proteins and miRNAs (Table 3).
The relationship between pyroptosis and OA has recently attracted attention. Pyroptosis produced during cell scorch death promotes the development of OA which contributes to pain associated with OA. The current focus of research remains on NLRP3 inflammatory vesicles. Undeniably, current experimental evidence in vivo and in vitro strongly suggests a close relationship between pyroptosis and OA. However, the molecular regulatory mechanisms of the relevant signaling pathways and the interconnections between these factors have not been fully elucidated. Few studies have reported on the link between pyroptosis, non-coding RNAs and OA.
Ferroptosis is an iron-dependent, non-apoptotic form of cell death that is distinct from apoptosis, pyroptosis, or necrosis. The main features of ferroptosis are lipid peroxidation and iron overload. New mechanisms and novel targets have been identified in studies of tumors (including hepatocellular carcinoma, pancreatic cancer, breast cancer, renal clear cell carcinoma), neurological diseases (including Alzheimer’s disease, Parkinson’s disease), cardiovascular diseases (including myocardial injury, ischemia-reperfusion, hemorrhagic stroke), and chronic diseases (including OA, rheumatoid arthritis). This provides novel perspectives and strategies for the treatment of related diseases. The occurrence of ferroptosis involves the expression and regulation of multiple genes, with complex signaling pathways and mechanisms that have not been fully elucidated. Currently available studies cannot fully reveal the relationship between ferroptosis and disease, and more research is needed in this area.
In conclusion, apoptosis, ferroptosis and pyroptosis have important roles in the development of OA, but deeper studies are needed. Exploring the relationship between OA and cell death can provide a theoretical basis and enable the development of translational strategies towards curing OA.
References 212
- 1.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
- 2.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
- 3.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
- 4.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
- 5.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
- 6.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
- 7.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
- 8.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
- 9.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
- 10.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
- 11.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
- 12.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
- 13.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
- 14.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
- 15.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
- 16.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
- 17.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
- 18.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
- 19.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
- 20.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
- 21.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
- 22.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
- 23.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
- 24.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
- 25.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
- 26.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
- 27.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
- 28.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
- 29.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
- 30.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
- 31.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
- 32.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
- 33.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
- 34.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
- 35.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
- 36.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
- 37.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
- 38.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
- 39.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
- 40.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
Cited by papers we hold 8
- Fighting age-related orthopedic diseases: focusing on ferroptosis · 2023No notice
- The double-edged functions of necroptosis · 2023No notice
- The gut microbiota metabolite capsiate regulate SLC2A1 expression by targeting HIF‐1α to inhibit knee osteoarthritis‐induced ferroptosis · 2023No notice
- Osteoarthritis: pathogenic signaling pathways and therapeutic targets · 2023No notice
- Lipid peroxidation in osteoarthritis: focusing on 4-hydroxynonenal, malondialdehyde, and ferroptosis · 2023No notice
- Evidence of pyroptosis and ferroptosis extensively involved in autoimmune diseases at the single-cell transcriptome level · 2022No notice
- Therapeutic application of quercetin in aging-related diseases: SIRT1 as a potential mechanism · 2022No notice
- Current understanding of osteoarthritis pathogenesis and relevant new approaches · 2022No notice
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.